Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress
May 12, 2021 on track for
Phase III European trial in stage IIIB/C melanoma. Opening of additional clinical centers to boost recruitment rate is ongoing. E
Fibromun
Philogen is well capitalized, about
th the
here (https://us06web.zoom.us/webinar/register/WN nEuoFxsHTXSTdtS4RBslYg)
Siena (Italy), 12 May 2021 - (Globe Newswire) - Philogen S.p.A. (BIT:PHIL) - a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor targeting antibodies and small molecule ligands, is pleased to announce progress updates for its fully-owned immunocytokine and small molecule programs.
Philogen S.p.A.: Philogen Announces Publication of Best-in-Class FAP-Targeting Small Molecule Ligand (OncoFAP) in PNAS
(i) Study shows impressive tumor uptake of OncoFAP with unprecedented selectivity against healthy organs - (ii) OncoFAP-based molecules are currently being developed for the imaging and therapy of cancer
SIENA, ITALY / ACCESSWIRE / April 12, 2021 / Philogen S.p.A., a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor targeting antibodies and small molecule ligands, is pleased to announce a publication describing the development and the
in vivo characterization of OncoFAP, a best-in-class FAP-targeting small molecule for applications in cancer and inflammation. The paper entitled An Ultra-High Affinity Small Organic Ligand of Fibroblast Activation Protein for Tumor Targeting Applications was published in the peer-reviewed journal